Marksans Pharma Limited has informed the Exchange about Investor Presentation
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma filed its Q1FY26 investor presentation showing revenue of ₹620 cr, up 5% year-on-year but down 12.5% sequentially due to seasonal softness. Gross profit grew 8.9% YoY to ₹358 cr with margin improving to 57.8%. However, EBITDA fell 22% YoY to ₹100 cr and EBITDA margin dropped sharply from 21.7% to 16.1%, while net profit declined 34.7% to ₹58 cr. Management attributed the margin pressure to one-time ECL provision of ₹10.48 cr for the emerging markets division, forex loss of ₹6.2 cr, higher employee costs at the newly acquired Goa facility, and elevated lease-related finance costs. The company ended the quarter with a strong cash balance of ₹711 cr and generated ₹48.7 cr in operating cash flow. Management outlined a strategic roadmap targeting ₹3,000 cr revenue in two years, doubling US business, climbing to top 3 Indian pharma position in the UK, and scaling India capacity from 8 bn to 16 bn units.
Short-term pressure on profitability from one-time charges and ramp-up costs may keep the stock volatile, but management views these as transient and pointed to early signs of demand recovery in Q2. Strong cash position, 100+ product pipeline, and clear multi-year growth targets support the long-term thesis, though the stock has already rallied ~187% in two years, leaving limited room for disappointment.